Exacerbation of Rheumatoid Arthritis by Sodium Fluoride Treatment of Osteoporosis

Paul Duell, Charles H. Chesnut

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent studies have suggested that sodium fluoride therapy may be an effective treatment for vertebral osteoporosis. Unfortunately, the high frequency of side effects may limit the use of this treatment modality. This report documents the repeated exacerbation of rheumatoid arthritis on three occasions after the initiation of sodium fluoride therapy. This apparent complication of sodium fluoride treatment may be mediated by stimulation of leukocyte production of reactive oxygen species and other mediators of the acute inflammatory response. We suggest that sodium fluoride should be used cautiously in patients with rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)783-784
Number of pages2
JournalArchives of Internal Medicine
Volume151
Issue number4
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Sodium Fluoride
Osteoporosis
Rheumatoid Arthritis
Therapeutics
Reactive Oxygen Species
Leukocytes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Exacerbation of Rheumatoid Arthritis by Sodium Fluoride Treatment of Osteoporosis. / Duell, Paul; Chesnut, Charles H.

In: Archives of Internal Medicine, Vol. 151, No. 4, 1991, p. 783-784.

Research output: Contribution to journalArticle

@article{4969d3970c8c4adba359f0f780264f56,
title = "Exacerbation of Rheumatoid Arthritis by Sodium Fluoride Treatment of Osteoporosis",
abstract = "Recent studies have suggested that sodium fluoride therapy may be an effective treatment for vertebral osteoporosis. Unfortunately, the high frequency of side effects may limit the use of this treatment modality. This report documents the repeated exacerbation of rheumatoid arthritis on three occasions after the initiation of sodium fluoride therapy. This apparent complication of sodium fluoride treatment may be mediated by stimulation of leukocyte production of reactive oxygen species and other mediators of the acute inflammatory response. We suggest that sodium fluoride should be used cautiously in patients with rheumatoid arthritis.",
author = "Paul Duell and Chesnut, {Charles H.}",
year = "1991",
doi = "10.1001/archinte.1991.00400040121028",
language = "English (US)",
volume = "151",
pages = "783--784",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Exacerbation of Rheumatoid Arthritis by Sodium Fluoride Treatment of Osteoporosis

AU - Duell, Paul

AU - Chesnut, Charles H.

PY - 1991

Y1 - 1991

N2 - Recent studies have suggested that sodium fluoride therapy may be an effective treatment for vertebral osteoporosis. Unfortunately, the high frequency of side effects may limit the use of this treatment modality. This report documents the repeated exacerbation of rheumatoid arthritis on three occasions after the initiation of sodium fluoride therapy. This apparent complication of sodium fluoride treatment may be mediated by stimulation of leukocyte production of reactive oxygen species and other mediators of the acute inflammatory response. We suggest that sodium fluoride should be used cautiously in patients with rheumatoid arthritis.

AB - Recent studies have suggested that sodium fluoride therapy may be an effective treatment for vertebral osteoporosis. Unfortunately, the high frequency of side effects may limit the use of this treatment modality. This report documents the repeated exacerbation of rheumatoid arthritis on three occasions after the initiation of sodium fluoride therapy. This apparent complication of sodium fluoride treatment may be mediated by stimulation of leukocyte production of reactive oxygen species and other mediators of the acute inflammatory response. We suggest that sodium fluoride should be used cautiously in patients with rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0025897444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025897444&partnerID=8YFLogxK

U2 - 10.1001/archinte.1991.00400040121028

DO - 10.1001/archinte.1991.00400040121028

M3 - Article

C2 - 2012465

AN - SCOPUS:0025897444

VL - 151

SP - 783

EP - 784

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 4

ER -